Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

15.51 -0.49 (-3.06%)
Streaming Delayed Price Updated: 11:14 AM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? ↗
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool
News headline image
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? ↗
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet. 
Via The Motley Fool
Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump ↗
Via Chartmill
Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing ↗
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks. 
Via The Motley Fool
News headline image
NovoCure (NVCR) Q1 2026 Earnings Transcript ↗
NovoCure (NVCR) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
NovoCure (NVCR) Q4 2025 Earnings Call Transcript ↗
NovoCure (NVCR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
AI: The Great Disruptor or the Great Divider? ↗
Via Chartmill
News headline image
NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside ↗
H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax. 
Via Stocktwits
Topics Government
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Novocure Stock Surges Nearly 30% After Hours: FDA Clears First New Pancreatic Cancer Therapy In Almost Three Decades ↗
The stock is on track to record its best day since December 2024 if the overnight gains hold. 
Via Stocktwits
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novocure (NVCR) Q2 2025 Earnings Call Transcript ↗
Novocure (NVCR) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2025 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon ↗
If you have decades of investing runway left, consider these two top healthcare stocks. 
Via The Motley Fool
News headline image
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher ↗
Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.